Treatment of spasticity with dantrolene sodium.
D000293:Adolescent; D000328:Adult; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006429:Hemiplegia / Q000150:complications; D006801:Humans; D006827:Hydantoins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009127:Muscle Rigidity / Q000188:drug therapy; D009578:Nitrobenzenes / Q000627:therapeutic use*; D010264:Paraplegia / Q000150:complications; D012018:Reflex / Q000187:drug effects*; D013035:Spasm / Q000150:complications / Q000188:drug therapy*; D013118:Spinal Cord Diseases / Q000150:complications
D005663:Furans; D006827:Hydantoins; D009125:Muscle Relaxants, Central; D009578:Nitrobenzenes